Home > Insider Trading > Filing (0001144204-19-045298)

Filing Details

Accession Number:: 0001144204-19-045298
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-09-19 19:12:21
Reporting Period:: 2019-09-17

Accepted Time:: 2019-09-19 19:12:21
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1773427	Springworks Therapeutics Inc.	SWTX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1437909	C Freda Lewis-Hall	C/O Springworks Therapeutics, Inc. 100 Washington Blvd. Stamford CT 06902		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-09-17	978,194	$0.00	978,194	No	4	C	Indirect	By: Pfizer Inc.
Common Stock	Acquisiton	2019-09-17	3,039,051	$0.00	4,017,245	No	4	C	Indirect	By: Pfizer Inc.
Common Stock	Acquisiton	2019-09-17	526,602	$0.00	4,543,847	No	4	C	Indirect	By: Pfizer Ventures (US) LLC
Common Stock	Acquisiton	2019-09-17	50,000	$18.00	4,593,847	No	4	P	Indirect	By: Pfizer Ventures (US) LLC

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By: Pfizer Inc.
No	4	C	Indirect	By: Pfizer Inc.
No	4	C	Indirect	By: Pfizer Ventures (US) LLC
No	4	P	Indirect	By: Pfizer Ventures (US) LLC

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Junior Series A Convertible Preferred Stock	Disposition	2019-09-17	978,194	$0.00	978,194	$0.00
Common Stock	Series A Convertible Preferred Stock	Disposition	2019-09-17	3,039,051	$0.00	3,039,051	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2019-09-17	526,602	$0.00	526,602	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of Junior Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Junior Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Junior Series A Convertible Preferred Stock has no expiration date.
Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date.
Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date.
Shares held by Pfizer Inc. ("Pfizer"). The reporting person is employed by Pfizer. The reporting person has no voting or dispositive power over the shares held by Pfizer or Pfizer Ventures (US) Holdings ("Pfizer Ventures"), a wholly owned subsidiary of Pfizer, and disclaims beneficial ownership of all such shares.
Shares held by Pfizer Ventures. The reporting person is employed by Pfizer. The reporting person has no voting or dispositive power over the shares held by Pfizer or Pfizer Ventures and disclaims beneficial ownership of all such shares.